H
Hui-Gene Therapeutics
Focused on R&D for single-gene disorders and has developed pilot pipes in neurodegenerative diseases
About Hui-Gene Therapeutics
HuidaGene Therapeutics is a biotechnology startup that operates in the medical research and development sector. The company focuses on developing innovative treatments for a range of diseases in the fields of neurology, ophthalmology, and myology. Its research pipelines include work on conditions such as MECP2 Duplication Syndrome, Huntington's Disease, Amyotrophic Lateral Sclerosis, inherited retinal dystrophies, age-related macular degeneration, retinitis pigmentosa, and Duchenne Muscular Dystrophy.
HuidaGene's business model revolves around the research, development, and commercialization of novel therapies. The company's primary clients are patients suffering from the aforementioned diseases, with a particular focus on rare and orphan diseases. Orphan diseases are conditions that affect a small percentage of the population, and the treatments for these conditions are often referred to as 'orphan drugs'.
The company generates revenue through the development and sale of these therapies. It is also actively seeking to expand its global collaborations, as evidenced by its participation in international conferences such as the BIO-Europe Fall Conference.
Recently, HuidaGene announced the dosing of its first patient in a multinational Phase 1/2 trial for inherited blindness. Additionally, the U.S. FDA has awarded both Rare Pediatric Disease and Orphan Drug Designations to HG204, a CRISPR RNA-editing therapy developed by HuidaGene for the treatment of MECP2 Duplication Syndrome.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | May 2022 | $0 | — | CD Capital · Kunlun Capital · Sherpa Venture Partners | ↗ |
| SERIES BOther financing | Jun 2021 | $62M | $248M | Undisclosed | — |
Growth signals
Latest recorded traffic for Hui-Gene Therapeutics is 2.8K monthly website visits, up 7.7% over the last three months. Hui-Gene Therapeutics's team declined 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hui-Gene Therapeutics in the Huangpu ecosystem
The Hui-Gene Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
CD Capital
WuXi AppTec
Series B and later2 investors entered at this stage
Kunlun Capital
Sherpa Venture Partners
Other known investors1 additional known investor
Chinese Academy Of Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hui-Gene Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hui-Gene Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









